Gesynta
Drug Discovery · Biotechnology
Overview
Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and increase blood flow in the body’s microvasculature, thereby providing safe and efficacious treatments for several serious diseases.
Funding and backers
Backers
3
Amboy Street Ventures, HealthCap
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Amboy Street Ventures 
HealthCap 
Industrifonden Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Novel therapies for metabolic inflammation and fibrosisThe Elgia team has discovered how metabolic stress drives inflammation and fibrosis…
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological…
Weatherden is a global drug development consultancy helping biotech and pharma realize the full potential of their science and investment.
Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination. Molecular Gates are small molecule drugs that…
Babylon is a drug development company pursuing a transformational treatment for Alzheimer’s. Meet our team and explore how we discover…
PharmEnable combines medicinal chemistry expertise with machine learning to find drug candidates for challenging protein targets. Founded…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
/PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the...
Read more
Report
First patient dosed in Gesynta Pharma
STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for endometriosis. Thi
Read more
Report
Orexos partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis
UPPSALA, Sweden, April 27, 2022/ PRNewswire/-- Orexo AB,, announces today that the companys partner Gesynta Pharma AB which owns all the rights to OX-MPI, a drug candidate for the treatment of systemic sclerosis, has been granted Orphan Drug Designation i
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Stockholm
Sweden
HQ
Wallingatan 24, Stockholm, 111 24, SE